Liminatus Pharma
LIMN
14 hedge funds and large institutions have $105K invested in Liminatus Pharma in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.7% less ownership
Funds ownership: 4.75% → 3.05% (-1.7%)
59% less capital invested
Capital invested by funds: $254K → $105K (-$149K)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38.3K |
| 2 |
Goldman Sachs
New York
|
+$6.94K |
| 3 |
SG
StoneX Group
New York
|
+$4.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.56K |
| 5 |
Barclays
London,
United Kingdom
|
+$743 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 2 |
Jane Street
New York
|
-$12.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.54K |
| 4 |
VF
Virtu Financial
New York
|
-$5K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$3.79K |
LIMN Hedge Fund Activity: Q2 2026 in Review
14 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q2 2026, worth a combined $105K — down 59% from $254K a quarter earlier.
Fund positioning in LIMN was balanced in Q2 2026: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 6 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $38.3K. The largest seller was Citadel Advisors, cutting an estimated $107K.
- 14 institutional investors held Liminatus Pharma (LIMN) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $105K of Liminatus Pharma stock for Q2 2026, down 59% quarter-over-quarter.
- 4 funds opened new Liminatus Pharma positions in Q2 2026 and 4 closed out, a net change of 0 holders.
- The largest Liminatus Pharma buyer in Q2 2026 was XTX Topco, an estimated $38.3K added.
- The largest Liminatus Pharma seller in Q2 2026 was Citadel Advisors, an estimated $107K sold.
Based on aggregated 13F filings for Q2 2026.